Hypertensive disorders of pregnancy are a major cause of maternal morbidity and mortality in the developed world 1 and their prevalence appears to be increasing in the United States. 2 Preeclampsia is new-onset hypertension after 20 weeks of pregnancy, typically with accompanying proteinuria that indicates altered kidney function. It is a serious complication, often triggering an early delivery, and can progress to eclampsia with maternal seizures and critical blood pressure elevations. Current clinical practice relies on blood pressure and proteinuria measurements routinely conducted as part of prenatal care as the basis for diagnosis.
Prior studies have examined RBP4 early in gestation in relation to preeclampsia risk and found either no association 9 or increased risks for early-onset severe preeclampsia. 10 When samples were collected at or after diagnosis, RBP4 has been reported to be elevated among preeclampsia cases in some studies 11, 12 but not different from controls in other studies 13, 14 and even lower than controls when samples were collected during the delivery hospital admission 15 or at diagnosis. 16 The cross-sectional, retrospective design, small sample size, assessment of RB4 once in pregnancy, and inadequate adjustment for confounders could explain the inconsistency in previous reports and these limitations hinder inference regarding pathophysiology and potential clinical utility.
Cholesterol and other maternal lipids are required to support the rapid growth and cell differentiation in the embryo and fetus. The potential role for altered maternal lipid levels as an early marker for adverse pregnancy outcomes has also been debated. Higher triglyceride levels measured in midpregnancy have been shown to predict preeclampsia 17 but not when measured earlier or later in pregnancy. 18 A rate of triglyceride change below the median from preconception over the course of pregnancy was associated with pregnancy loss and preterm birth 19 suggesting that a steeper increase in early pregnancy was protective.
No prior studies have examined longitudinal measures in pregnant women at risk for preeclampsia. Our aim was to examine repeated measures of maternal lipids and RBP4 over the course of pregnancy to evaluate the relationship of these biomarkers with preeclampsia and preterm birth risk.
SUBJECTS AND METHODS
Data are from the Calcium for Preeclampsia Prevention (CPEP) trial, a clinical trial conducted from 1992-1995 to evaluate whether calcium supplementation would prevent preeclampsia among 4,589 nulliparous women with singleton pregnancies. 20 We conducted a nested case-control study using stored serum samples. All cases of preterm preeclampsia (n = 63) and preterm birth (total n = 160; preterm without preeclampsia n = 107) were selected for analyses along with a random selection of preeclampsia cases at term (n = 104). The case definition for preeclampsia was previously established as hypertension (with diastolic blood pressure of at least 90 mm Hg on 2 occasions) and proteinuria (based on urine dipstick results on 2 occasions or 24-hour urine collection). 20, 21 The control group was comprised of randomly selected women (n = 136) who remained normotensive and normoglycemic throughout pregnancy without proteinuria, who also delivered a term infant without evidence of growth restriction. Controls and term preeclampsia cases were randomly selected based on the number of participants and cases in each CPEP study site in order to preserve the geographic distribution of the original trial. Sample size was based on providing statistical power for hypotheses related to the prediction of preeclampsia 22 and other related adverse pregnancy outcomes.
Nonfasting blood samples were collected before randomization to calcium supplement or placebo (prior to 21 weeks, 6 days of gestation) as well as at least twice during follow-up. We analyzed the baseline sample (prerandomization), a mid-pregnancy sample, collected between gestational weeks 22 to 34 and a third sample at >34 weeks when available. RBP-4 was measured in plasma using an enzyme-linked immunosorbant assay (ELISA) from R&D Systems (Minneapolis, MN). The assay coefficient of variation (CV) was <10%. Lipid determinations were performed in serum on the Roche Modular P Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN). Total cholesterol was measured using a cholesterol oxidase method (Roche Diagnostics) with a laboratory CV of 1.6%. High-density lipoprotein (HDL) cholesterol was measured directly using the Roche HDL cholesterol third generation homogenous enzymatic direct method (Roche Diagnostics) with a laboratory CV of 2.3%. Triglycerides were measured using the Roche Triglyceride Glycerol Blanked enzymatic colorimetric assay (Roche Diagnostics) with a laboratory CV of 2.1%. Methods for measurement of total cholesterol, HDL cholesterol, and triglyceride were monitored by the CDC/NHLBI Lipid standardization program. Low-density lipoprotein (LDL) cholesterol was measured directly using the homogenous enzymatic colorimetric Roche LDL-C second generation method (Roche Diagnostics) with a laboratory CV of 2.9%. Lipoprotein (a) (Lp(a)) was measured using an immunoturbidimetric assay by Randox Laboratories Limited, United Kingdom, adapted for use on the Roche Modular P Analyzer. The laboratory CV was 2.5%.
Participants were linked to stored biospecimens by a unique study identification number with no personally identifiable information. This study was exempted from Institutional Review Board review by the National Institutes of Health's Office of Human Subjects Research because it uses existing de-identified samples.
STATISTICAL ANALYSES
Descriptive statistics were calculated for participants' characteristics and biomarker levels at each of the three sample collection points. In cross-sectional analyses, we explored whether lipids and RBP4 levels measured at approximately week 15 of gestation predicted preeclampsia and preterm delivery. Crude and adjusted odds ratios (OR) and 95% confidence intervals (CI) were estimated using logistic regression models for the association of lipids and RBP4 levels at baseline with preterm preeclampsia, term preeclampsia, all preeclampsia (either term or preterm), and preterm delivery. Concentrations of all biomarkers had a skewed distribution, and, therefore, were transformed using natural logarithms. Non-HDL cholesterol was derived by subtracting HDL from total cholesterol, both measured as specified above, prior to log-transformation. Models were adjusted for age, race, body mass index, insurance status, current smoking, marital status, study center, and gestational age at the time of sampling (to account for the variation in time of blood draw during gestation). To examine the prediction of pregnancy complications, each biomarker was evaluated in relation to each outcome of interest separately. Next, models were run with only covariates, with covariates and all lipid biomarkers and finally, with covariates, lipid biomarkers, and RBP4. The area under the curve for the receiver operating characteristic curve for each model was calculated and a cross-validation was attempted. The mid-pregnancy sample was analyzed similarly. Since third samples were scarce for the preterm groups, they were only examined in the longitudinal analyses described below.
We also examined potential nonlinear associations between biomarkers levels and pregnancy outcomes. To this aim, we categorized the biomarkers using tertiles and explored the ORs and CIs for adverse pregnancy outcomes using the middle tertile as the reference group.
To describe the longitudinal trajectories of biomarkers throughout pregnancy in cases and controls, we used linear mixed models with fixed effects and an unstructured covariance matrix and reported the differences in repeated measures of biomarkers during gestation in women with preterm preeclampsia compared to controls. Adjusted means, derived from these longitudinal models, were plotted for each biomarker in each assessment period. These 3 periods of blood draw were originally designed in the study: <22.0 weeks of gestation, 22.0-34.0 weeks of gestation, and >34.0 weeks of gestation. For each time window, only one set of biomarker measurements per woman was included, regardless of whether she had additional blood draws. A similar approach was used in women with preterm delivery. Models were adjusted for age, race, body mass index, insurance status, current smoking, marital status, study center. Calcium treatment status was evaluated as a potential covariate but not included in the final model because it did not change the results. Statistical analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC).
RESULTS
As the CPEP was designed to study high-risk women, women in the study were young (mean age 20-21), on average had a body mass index in the overweight category (>25) and about half of the sample were Black (Table 1) . Most women (85-96%) had no private insurance and <30% were married. The gestational age at biospecimen collection was similar for all groups.
Per log-unit increment in the RBP4 concentrations measured at baseline (15 weeks on average) was associated with statistically significant 4-to 8-fold increased risk for preterm preeclampsia (Table 2 ). Adjustment for known risk factor covariates and gestational age at specimen collection increased the risk estimates. In contrast to preterm preeclampsia, RBP4 was not associated with preeclampsia at term. Combining all preeclampsia cases together attenuates the RPB4 results (OR = 1.66, CI: 0.56-4.92). With regard to all preterm delivery (with or without preeclampsia), RBP4 levels were elevated at baseline but the associations were not significant. In analysis with tertiles of RBP4, we observed that compared to the middle tertile, the lowest tertile was associated with a lower odds of preterm preeclampsia (OR = 0.41, CI: 0.18, 0.95), but no significant association was observed with the highest tertile.
In general, cholesterol concentrations at baseline (HDL, LDL, and non-HDL) were inversely related to risk for preterm preeclampsia, term preeclampsia, and preterm birth, suggesting a reduced risk with higher lipids but these were nonsignificant. Analysis using tertiles of cholesterol measures showed no threshold effect. The results of the Lp(a) and triglycerides measured at baseline were also null for all outcomes; however, we observed a nonlinear relation associated with the baseline triglycerides, where both low (<101) and high triglyceride levels (>139) were associated with preterm When all biomarkers were included in the same model, baseline RBP4 remained a significant predictor of preterm preeclampsia with an adjusted OR = 8.29 (1.65, 41.66). Adding RBP4 to a prediction model increased the area under the curve to 0.7040, an improvement over the model with covariates only (area under the curve = 0.6775) and covariates plus lipids (area under the curve = 0.6800) but an attempt at crossvalidation (leave-one-out) did not replicate the initial finding.
Triglycerides measured in the second, mid-pregnancy sample remained associated with term preeclampsia with a 2-to 3-fold increased risk (adjusted OR = 3.31, CI: 1.21-9.07). No other lipids or RBP4 measured at approximately week 27 were significantly related to term preeclampsia.
We also examined risk for preterm delivery that was not related to preeclampsia, but no biomarkers were significantly related to risk and point estimates were attenuated at baseline in this subsample (data not shown). Second samples were only available for 18 cases of preterm delivery without preeclampsia, which precluded multivariate analyses.
Longitudinal models revealed that women with preterm preeclampsia and also women with preterm delivery (with or without preeclampsia) had consistently higher levels of RBP4, compared to controls throughout pregnancy (Figures 1 and 2) . Although the results were nonsignificant, women with preterm preeclampsia had consistently higher levels of Lp(a) throughout pregnancy compared to controls. Furthermore, the pattern of triglycerides throughout pregnancy indicated that women with preterm preeclampsia had a steeper slope for triglyceride increase from time 1 to time 2 compared to controls (P for slope difference = 0.07). A similar distinct pattern of triglyceride increase was observed for preterm delivery (Figure 2 ).
DISCUSSION
We found that RBP4 levels were strongly and positively associated with early-onset preeclampsia with a 4-to Figure 1 . Adjusted mean levels* of retinol-binding protein 4 and lipids among women with preterm preeclampsia (PE) and controls at 3 time points during pregnancy: <22 weeks, 22-34 weeks, and >34 weeks, Calcium for Preeclampsia Prevention Trial, 1992-1995. *Means were adjusted for age, race, body mass index, insurance status, current smoking, marital status, and study center. Abbreviations: RBP4, retinol-binding protein 4; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp(a), Lipoprotein (a); TG, Triglycerides.
8-fold increase in risk, but no associations were observed for preeclampsia at term. Triglyceride levels at mid-pregnancy were associated with a 2-to 3-fold increase in risk for both early and term preeclampsia. We also observed consistent increases in risk for preterm delivery associated with both RBP4 and triglyceride levels at mid-pregnancy, but did not have a sufficient sample size to assess this risk only among preterm births without preeclampsia. In contrast to Laughon et al., 19 we observed that a steeper increase in triglycerides in early pregnancy was associated with an increased preterm birth risk rather than a protective effect.
Our findings for triglycerides are supported by a small study 23 that measured lipids in 26 normotensive and 27 preeclamptic pregnancies. Triglycerides were elevated in patients with preeclampsia but no differences were observed for total, HDL, or LDL cholesterol. Given our longitudinal sampling and larger study, we were able to observe that both low and high triglyceride levels early in pregnancy were associated with a doubling of preeclampsia risk and this relation became linear, with higher risk associated with higher triglyceride levels, in the second trimester for both term and preterm preeclampsia.
Preeclampsia cases appeared to have higher total cholesterol, triglycerides, and LDL in a prospective study of 251 pregnant women with early maternal blood samples (4-12 weeks) in which 16 mild and 10 severe preeclampsia cases developed. 24 Our baseline samples were generally later in pregnancy, on average 15 weeks (range 2-21 weeks), and nonfasting which might account for these differences, but we also have a larger sample of cases and adjustment for gestational age at sampling did not have a substantive impact on the risk estimates. A single first trimester screening sample analyzed for RBP4 among 14 preeclampsia cases and 11 control pregnancies found no difference related to subsequent preeclampsia risk 14 but this might be due to a mixing of preterm and term cases since the gestational age at diagnosis was not described.
Using a 1-time blood sample collected at the time of diagnosis, Vaisbuch et al. reported an association between RBP4 and preeclampsia, with a stronger relationship observed for early-onset disease among 39 women; however, the association may have been the result of preeclampsia rather than antedating it. 11 On the other hand, RBP4 did not appear to be related to clinical measures or lipids among women with blood samples collected after diagnosis in a sample of 16 preeclampsia patients compared with 20 controls. 13 In contrast to our findings, a small study in Japan found RBP4 measured at diagnosis was not different between 18 healthy pregnant women and 18 early-onset preeclampsia cases, but did see higher RBP4 increased in later onset cases (n = 41 in each group). 25 Our study benefits from detailed clinical data and longitudinal serum samples from the CPEP Trial. 20 With more than 60 cases of preterm preeclampsia and over 100 cases of preeclampsia at term, this is the largest studies to relate preeclampsia to RBP4, one of the few with prospective measurements and the only study with longitudinal measures across gestation. However, since women had a high risk for preeclampsia by design (nulliparous, majority Black and overweight, etc.), our findings might not be generalizable to a lower-risk obstetric cohort. We are also limited in our assessment of lipids by having only nonfasting samples available, although we note that fasting status has been found to remain predictive of cardiovascular events as any differences in fasting time should be random with respect to the development of later disease. 26 In consideration of these issues, we measured LDL directly, rather than calculating it based on total cholesterol and HDL levels. We note that our samples were stored for up to 20 years which could impact the absolute values of the lipids we studied. Reassuringly, long-term storage of lipids, including triglycerides, yielded stable results after 8-10 years in similar conditions. 27 Since our main findings are based on the relative concentrations rather than absolute values, we expect any potential storage-related variation is independent of diagnosis and thus would not substantively impact the associations we observed. Finally, we had a relatively small number of samples available among preterm deliveries without preeclampsia which precluded a complete independent analysis of preterm birth. It is somewhat reassuring that the majority of those cases (83%) had a spontaneous onset of labor, so they were less likely due to medical indications.
In conclusion, most prior studies have been limited by single blood samples, often collected after diagnosis, among relatively small numbers of preeclampsia cases and control pregnant women. In our larger study based on a clinical trial of women at risk for preeclampsia, we find that RBP4 is significantly and consistently related to preterm preeclampsia but not preeclampsia that developed at term. RBP4 is also associated with an increased preterm birth risk when measured at mid-pregnancy. Triglyceride levels were elevated in mid-pregnancy among women who developed preeclampsia and among those who delivered preterm. RBP4 merits further investigation in relation to preeclampsia. If our results are confirmed, RBP4 may be helpful in identifying women early in pregnancy who are at high risk for preterm preeclampsia.
